- Conditions
- Core Binding Factor Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Gemtuzumab Ozogamicin, Multigated Acquisition Scan, Venetoclax
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • La Jolla, California • Pembroke Pines, Florida + 61 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 548
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Metastatic Prostate Carcinoma, Multiple Myeloma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Chart Review, Paracentesis, Positron Emission Tomography
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 147
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more
- Conditions
- Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone, Metastatic Tumor to the Bone
- Interventions
- 153-Sm-DOTMP (Samarium-153-DOTMP)
- Drug
- Lead sponsor
- QSAM Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Columbia, Missouri • New Brunswick, New Jersey + 1 more
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Interventions
- Fluorine F 18 Sodium Fluoride
- Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Pomalidomide, Quality-of-Life Assessment, Questionnaire Administration, Selinexor, X-Ray Imaging, Computed Tomography, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Questionnaire Administration, Selvigaltin
- Procedure · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- American ginseng, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 326
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 208 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab, Venetoclax
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 29
- States / cities
- Greenwich, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 23 more
- Conditions
- Osteochondral Defect
- Interventions
- osteochondral transplant on the femoral condyle
- Procedure
- Lead sponsor
- AlloSource
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Los Angeles, California • Redwood City, California + 3 more
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Androgen Therapy, Apalutamide, Docetaxel, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, PSMA PET Scan, Biospecimen Collection, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 213
- States / cities
- Tucson, Arizona • Dublin, California • Fremont, California + 172 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Zirconium Zr 89 Girentuximab
- Procedure · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Tegavivint, Bone Marrow Biopsy, Bone Marrow Aspiration
- Procedure · Drug
- Lead sponsor
- Lapo Alinari
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Renal Transplant Donor of Left Kidney, Renal Transplant Donor of Right Kidney
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 4,415 participants
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Multigated Acquisition Scan, Odronextamab, Positron Emission Tomography, Ultrasound Imaging, Zanubrutinib
- Procedure · Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging of the Heart
- Drug · Procedure
- Lead sponsor
- Seema Bhat
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Bone Mineral Density, Hemophilia A, Hemophilia B
- Interventions
- DXA scan + MRI
- Other
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 25 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sarcoma
- Interventions
- positron emission tomography computed tomography (PET/CT)
- Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib, Revumenib, Echocardiography Test, Multigated Acquisition Scan
- Procedure · Drug
- Lead sponsor
- Uma Borate
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Chapel Hill, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Tooth Extraction Status Nos
- Interventions
- tooth extraction, CBCT scan, Anesthesia, clinical measurements, Biodegradable sponge (type I bovine collagen), 10µg of pSil-miR200c, cross mattress suture, 10µg of PMIS miR200a plasmids, 5µg of pSil-miR200c and 5µg of PMIS miR200a, Blood, Photos/videos, Wound fluid, saliva, periapical xray, PVS impression
- Procedure · Radiation · Drug + 1 more
- Lead sponsor
- Gustavo Avila-Ortiz DDS, MS, PhD
- Other
- Eligibility
- 25 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 114
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
- Conditions
- Osteoporosis
- Interventions
- Dual Energy CT (DECT), DEXA
- Radiation
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Prostate Cancer
- Interventions
- Magnetic Resonance Imaging (DCE-MRI), AZD2171, Prednisone
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington